Sunday, 11 June 2017

Detailed Study of the Global Lymphoma Drugs Market 2017-2021

Report Global Lymphoma Drugs Market 2017-2021 is a new market research publication announced by Reportstack. 
Report Outline: Lymphoma is a type of cancer that affects the immune system of the body. Specifically, it affects the lymphocytes, a type of white blood cell. The lymphocytes are part of the immune system and help the body to fight infections. The cancerous lymphocytes grow uncontrollably and collect in different portions of the body; lymph node can be one of the most common sites for lymphoma development. The lymph nodes are found throughout the body particularly in the groin, neck, and under the arms. Lymphoma can also develop in the deeper lymph nodes such as those in bone marrow and spleen. Very rarely this disease can start in other parts of the body such as stomach, breast, skin, brain, bowel, or liver.
For detailed report with TOC, please click here ​Global Lymphoma Drugs Market 2017-2021
Market Growth: The global lymphoma drugs market to grow at a CAGR of 8.02% during the period 2017-2021.
Key vendors • Celgene
• F. Hoffmann-La Roche
• Johnson & Johnson
• Seattle Genetics
Other prominent vendors • Amgen
• Bristol-Myers Squibb
• Gilead Sciences
• GlaxoSmithKline
• Novartis
• Pfizer
• Takeda Pharmaceuticals
• Teva Pharmaceutical Industries
Regions Covered: 
• Americas
Companies Mentioned
Celgene, F. Hoffmann-La Roche, Johnson & Johnson, Seattle Genetics, Amgen, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Novartis, Pfizer, Takeda Pharmaceuticals, and Teva Pharmaceutical Industries.
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research

No comments:

Post a Comment